Allogeneic blood stem cell transplantation after a reduced-intensity, preparative regimen: a pilot study in patients with refractory malignancies

Cancer
Paolo PedrazzoliGioacchino Robustelli Della Cuna

Abstract

The immune-mediated graft-versus-tumor (GVT) effect plays a therapeutic role in the treatment of patients with hematologic malignancies who undergo allogeneic hematopoietic stem cell transplantation (HSCT). More recently, it was reported that a GVT effect also occurred in patients who underwent transplantation for metastatic renal carcinoma. The authors carried out a pilot trial of allogeneic transplantation after a reduced-intensity, preparative regimen in patients with refractory malignancies, including solid tumors. The objectives of the current study were to evaluate the feasibility of this approach in terms of toxicity and engraftment and to document evidence of GVT effects. Seventeen patients with Stage IV malignancies (7 patients with renal cell carcinoma, 3 patients with sarcoma, 2 patients with breast carcinoma, 2 patients with Hodgkin disease, 1 patient with ovarian carcinoma, 1 patient with melanoma, and 1 patient with both melanoma and renal cell carcinoma) that were not amenable to further conventional treatment were enrolled. The median patient age was 43 years (range, 10-60 years). The Eastern Cooperative Oncology Group performance status (PS) was 0-1 in 11 patients and 2-3 in 6 patients. Preparative treatment co...Continue Reading

References

Aug 11, 2006·Der Urologe. Ausg. A·A HaferkampM Hohenfellner
Sep 16, 2004·Springer Seminars in Immunopathology·Yago NietoElizabeth J Shpall
Mar 2, 2011·Cancer Biotherapy & Radiopharmaceuticals·Robert O Dillman
Jul 20, 2005·Anti-cancer Drugs·D J van SpronsenP H M De Mulder
Jun 26, 2007·Journal of Immunotherapy·Edward PeresRoger Dansey
Dec 10, 2003·Journal of Pediatric Hematology/oncology·Kimberly A KasowWing Leung
Oct 31, 2006·Expert Review of Anticancer Therapy·Jan RoigasGero Massenkeil
Dec 13, 2005·Expert Review of Anticancer Therapy·Robert O Dillman
Jun 29, 2011·Expert Review of Anticancer Therapy·Marco BregniSolid Tumor Working Party of EBMT
Oct 16, 2004·Expert Review of Anticancer Therapy·Igor Espinoza-Delgado, Richard Childs
Mar 23, 2011·Expert Opinion on Biological Therapy·Scott S TykodiJohn A Thompson
Oct 2, 2003·Expert Opinion on Biological Therapy·Sakti Chakrabarti, Richard Childs
Jul 1, 2006·Cancer Investigation·Brian L Abbott
Sep 9, 2009·British Journal of Haematology·Olle RingdenMichael Uhlin
Oct 13, 2005·Cancer·Jacopo PeccatoriEuropean Bone Marrow Transplantation Solid Tumor Working Party
Sep 9, 2005·Hematological Oncology·Brian L Abbott
Apr 1, 2004·International Journal of Cancer. Journal International Du Cancer·Daniela MontagnaRita Maccario
May 10, 2007·Clinical Transplantation·Tak YunKyoo-Hyung Lee
Apr 20, 2010·Asia-Pacific Journal of Clinical Oncology·Thean Hsiang TanDesmond Yip
Jun 28, 2005·Critical Reviews in Oncology/hematology·D J van SpronsenP H M De Mulder
Jun 10, 2005·Cancer Treatment Reviews·P NieboerW T A van der Graaf
Mar 21, 2003·Journal of Nippon Medical School = Nippon Ika Daigaku Zasshi·Kenji Tajika
Jan 16, 2007·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Brenda M SandmaierRichard Childs
Jul 21, 2007·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Kazutaka NakayamaNaoto T Ueno
Aug 18, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Naoto T UenoRoy B Jones
Oct 11, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Roger K StrairEdmund C Lattime
Dec 13, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·James C Yang, Richard Childs
Sep 1, 2004·The Lancet Oncology·Lyndon GommersallHitendra R H Patel
Sep 27, 2005·Transplantation Proceedings·F Carnevale-SchiancaM Aglietta
Jun 24, 2003·Transplantation·Michel ToungouzMichel Goldman
Nov 3, 2005·Nature Clinical Practice. Oncology·Manit AryaHitendra R H Patel

Citations

May 10, 1979·The New England Journal of Medicine·P L WeidenR F Storb
Aug 1, 1980·The American Journal of Medicine·H M ShulmanE D Thomas
Jan 1, 1996·Annals of Surgical Oncology·C J BartelsJ C Yang
Mar 28, 1997·International Journal of Cancer. Journal International Du Cancer·S MoreckiS Slavin
Mar 21, 1998·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Naoto T UenoRichard E Champlin
Jan 22, 2000·The Journal of Clinical Investigation·C A HuangD H Sachs
Mar 29, 2000·Bone Marrow Transplantation·J O BayDidier Blaise

Related Concepts

Ovarian Diseases
Sarcoma
Antineoplastic Agents
Thrombocytopenia
Hematology (Discipline)
Cyclophosphamide
Neutropenia
Hematologic Neoplasms
Epithelial Ovarian Cancer
Acute GVH Disease

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.